Even though no kinase inhibitors have received FDA approval for MM therapy, preclinical exploration for possible therapeutic targets in MM has yielded the potential results, and small molecule protein kinase inhibitors have been under investigation in its application to MM30. The gene discussed is WEE1; the disease is Miyoshi myopathy.